News articles about Inogen (NASDAQ:INGN) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inogen earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the medical technology company an impact score of 45.8150120024108 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Zacks: Analysts Expect Inogen Inc (INGN) Will Post Quarterly Sales of $62.60 Million (americanbankingnews.com)
- Contrasting Inogen (INGN) & Cardiovascular Systems (CSII) (americanbankingnews.com)
- BidaskClub Upgrades Inogen (INGN) to Buy (americanbankingnews.com)
- Alison Bauerlein Sells 15,911 Shares of Inogen Inc (INGN) Stock (americanbankingnews.com)
Shares of Inogen (INGN) opened at $127.35 on Wednesday. Inogen has a 52-week low of $73.05 and a 52-week high of $134.97. The firm has a market capitalization of $2,665.80, a price-to-earnings ratio of 97.96, a PEG ratio of 3.52 and a beta of 1.03.
In other news, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $119,060. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Alison Bauerlein sold 15,911 shares of the firm’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $124.48, for a total value of $1,980,601.28. Following the transaction, the executive vice president now owns 20,072 shares in the company, valued at approximately $2,498,562.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,369 shares of company stock valued at $20,697,980. Corporate insiders own 5.31% of the company’s stock.
WARNING: This story was originally posted by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/2018/03/14/inogen-ingn-receives-news-impact-score-of-0-11/1970820.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.